v2021a Search Results


incucyte software  (Sartorius AG)
99
Sartorius AG incucyte software
EphA3 CAR T cells are functional against adult and pediatric glioma. ( A ) Schematic of second generation CAR constructs; ( B ) flow cytometry of cell surface expression of EphA3 (red) and HER2 (blue) CAR, as detected using anti-G4S protein tag antibody, and the percentage of CAR+ of T-cell population shown for three independent human donors; activated CD4 + EphA3-CAR T cells after 16 hour co-culture with U251CL tumor cells, or CD3/CD28 beads as positive control showing ( C ) %CD137 expression as detected using flow cytometry and ( D ) IFNγ and TNF secretion (pg/mL) into the culture. Transduction efficiencies of CD4+ GFP+ (empty vector) or CD4+ G4S+ CAR T cells shown in ( C ) and ( D ) for each group are as follows: EV 62%, HER2 94%, EphA3 79%. Shown is mean of triplicates (n=3± STDEV, *p<0.05 using two-way analysis of variance); ( E ) <t>IncuCyte</t> killing assay of 2.5:1 ratio of CD8 + CAR T cells co-cultured with adult U251CL glioma cells or pediatric SU-DIPG36GL tumor cells over 24 hours. Transduction efficiencies for CD8+ GFP+ (empty vector) or CD8+ G4S+ CAR T cells for each group are as follows: EV 41%, HER2 43%, EphA3 25%. CAR, chimeric antigen receptor; EphA3, Ephrin type-A receptor 3; HER2, Human epidermal receptor protein 2; IFNγ, interferon gamma; scFv, single-chain variable fragment; TNF, Tumour necrosis factor.
Incucyte Software, supplied by Sartorius AG, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/incucyte software/product/Sartorius AG
Average 99 stars, based on 1 article reviews
incucyte software - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
matlab v2020a  (MathWorks Inc)
90
MathWorks Inc matlab v2020a
EphA3 CAR T cells are functional against adult and pediatric glioma. ( A ) Schematic of second generation CAR constructs; ( B ) flow cytometry of cell surface expression of EphA3 (red) and HER2 (blue) CAR, as detected using anti-G4S protein tag antibody, and the percentage of CAR+ of T-cell population shown for three independent human donors; activated CD4 + EphA3-CAR T cells after 16 hour co-culture with U251CL tumor cells, or CD3/CD28 beads as positive control showing ( C ) %CD137 expression as detected using flow cytometry and ( D ) IFNγ and TNF secretion (pg/mL) into the culture. Transduction efficiencies of CD4+ GFP+ (empty vector) or CD4+ G4S+ CAR T cells shown in ( C ) and ( D ) for each group are as follows: EV 62%, HER2 94%, EphA3 79%. Shown is mean of triplicates (n=3± STDEV, *p<0.05 using two-way analysis of variance); ( E ) <t>IncuCyte</t> killing assay of 2.5:1 ratio of CD8 + CAR T cells co-cultured with adult U251CL glioma cells or pediatric SU-DIPG36GL tumor cells over 24 hours. Transduction efficiencies for CD8+ GFP+ (empty vector) or CD8+ G4S+ CAR T cells for each group are as follows: EV 41%, HER2 43%, EphA3 25%. CAR, chimeric antigen receptor; EphA3, Ephrin type-A receptor 3; HER2, Human epidermal receptor protein 2; IFNγ, interferon gamma; scFv, single-chain variable fragment; TNF, Tumour necrosis factor.
Matlab V2020a, supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/matlab v2020a/product/MathWorks Inc
Average 90 stars, based on 1 article reviews
matlab v2020a - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
track manager v2021.03.1  (QUALISYS LIMITED)
90
QUALISYS LIMITED track manager v2021.03.1
EphA3 CAR T cells are functional against adult and pediatric glioma. ( A ) Schematic of second generation CAR constructs; ( B ) flow cytometry of cell surface expression of EphA3 (red) and HER2 (blue) CAR, as detected using anti-G4S protein tag antibody, and the percentage of CAR+ of T-cell population shown for three independent human donors; activated CD4 + EphA3-CAR T cells after 16 hour co-culture with U251CL tumor cells, or CD3/CD28 beads as positive control showing ( C ) %CD137 expression as detected using flow cytometry and ( D ) IFNγ and TNF secretion (pg/mL) into the culture. Transduction efficiencies of CD4+ GFP+ (empty vector) or CD4+ G4S+ CAR T cells shown in ( C ) and ( D ) for each group are as follows: EV 62%, HER2 94%, EphA3 79%. Shown is mean of triplicates (n=3± STDEV, *p<0.05 using two-way analysis of variance); ( E ) <t>IncuCyte</t> killing assay of 2.5:1 ratio of CD8 + CAR T cells co-cultured with adult U251CL glioma cells or pediatric SU-DIPG36GL tumor cells over 24 hours. Transduction efficiencies for CD8+ GFP+ (empty vector) or CD8+ G4S+ CAR T cells for each group are as follows: EV 41%, HER2 43%, EphA3 25%. CAR, chimeric antigen receptor; EphA3, Ephrin type-A receptor 3; HER2, Human epidermal receptor protein 2; IFNγ, interferon gamma; scFv, single-chain variable fragment; TNF, Tumour necrosis factor.
Track Manager V2021.03.1, supplied by QUALISYS LIMITED, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/track manager v2021.03.1/product/QUALISYS LIMITED
Average 90 stars, based on 1 article reviews
track manager v2021.03.1 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
geneious prime ® software  (Biomatters Ltd)
90
Biomatters Ltd geneious prime ® software
EphA3 CAR T cells are functional against adult and pediatric glioma. ( A ) Schematic of second generation CAR constructs; ( B ) flow cytometry of cell surface expression of EphA3 (red) and HER2 (blue) CAR, as detected using anti-G4S protein tag antibody, and the percentage of CAR+ of T-cell population shown for three independent human donors; activated CD4 + EphA3-CAR T cells after 16 hour co-culture with U251CL tumor cells, or CD3/CD28 beads as positive control showing ( C ) %CD137 expression as detected using flow cytometry and ( D ) IFNγ and TNF secretion (pg/mL) into the culture. Transduction efficiencies of CD4+ GFP+ (empty vector) or CD4+ G4S+ CAR T cells shown in ( C ) and ( D ) for each group are as follows: EV 62%, HER2 94%, EphA3 79%. Shown is mean of triplicates (n=3± STDEV, *p<0.05 using two-way analysis of variance); ( E ) <t>IncuCyte</t> killing assay of 2.5:1 ratio of CD8 + CAR T cells co-cultured with adult U251CL glioma cells or pediatric SU-DIPG36GL tumor cells over 24 hours. Transduction efficiencies for CD8+ GFP+ (empty vector) or CD8+ G4S+ CAR T cells for each group are as follows: EV 41%, HER2 43%, EphA3 25%. CAR, chimeric antigen receptor; EphA3, Ephrin type-A receptor 3; HER2, Human epidermal receptor protein 2; IFNγ, interferon gamma; scFv, single-chain variable fragment; TNF, Tumour necrosis factor.
Geneious Prime ® Software, supplied by Biomatters Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/geneious prime ® software/product/Biomatters Ltd
Average 90 stars, based on 1 article reviews
geneious prime ® software - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
originpro v2021b software  (OriginLab corp)
90
OriginLab corp originpro v2021b software
EphA3 CAR T cells are functional against adult and pediatric glioma. ( A ) Schematic of second generation CAR constructs; ( B ) flow cytometry of cell surface expression of EphA3 (red) and HER2 (blue) CAR, as detected using anti-G4S protein tag antibody, and the percentage of CAR+ of T-cell population shown for three independent human donors; activated CD4 + EphA3-CAR T cells after 16 hour co-culture with U251CL tumor cells, or CD3/CD28 beads as positive control showing ( C ) %CD137 expression as detected using flow cytometry and ( D ) IFNγ and TNF secretion (pg/mL) into the culture. Transduction efficiencies of CD4+ GFP+ (empty vector) or CD4+ G4S+ CAR T cells shown in ( C ) and ( D ) for each group are as follows: EV 62%, HER2 94%, EphA3 79%. Shown is mean of triplicates (n=3± STDEV, *p<0.05 using two-way analysis of variance); ( E ) <t>IncuCyte</t> killing assay of 2.5:1 ratio of CD8 + CAR T cells co-cultured with adult U251CL glioma cells or pediatric SU-DIPG36GL tumor cells over 24 hours. Transduction efficiencies for CD8+ GFP+ (empty vector) or CD8+ G4S+ CAR T cells for each group are as follows: EV 41%, HER2 43%, EphA3 25%. CAR, chimeric antigen receptor; EphA3, Ephrin type-A receptor 3; HER2, Human epidermal receptor protein 2; IFNγ, interferon gamma; scFv, single-chain variable fragment; TNF, Tumour necrosis factor.
Originpro V2021b Software, supplied by OriginLab corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/originpro v2021b software/product/OriginLab corp
Average 90 stars, based on 1 article reviews
originpro v2021b software - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
v2021b  (MathWorks Inc)
90
MathWorks Inc v2021b
EphA3 CAR T cells are functional against adult and pediatric glioma. ( A ) Schematic of second generation CAR constructs; ( B ) flow cytometry of cell surface expression of EphA3 (red) and HER2 (blue) CAR, as detected using anti-G4S protein tag antibody, and the percentage of CAR+ of T-cell population shown for three independent human donors; activated CD4 + EphA3-CAR T cells after 16 hour co-culture with U251CL tumor cells, or CD3/CD28 beads as positive control showing ( C ) %CD137 expression as detected using flow cytometry and ( D ) IFNγ and TNF secretion (pg/mL) into the culture. Transduction efficiencies of CD4+ GFP+ (empty vector) or CD4+ G4S+ CAR T cells shown in ( C ) and ( D ) for each group are as follows: EV 62%, HER2 94%, EphA3 79%. Shown is mean of triplicates (n=3± STDEV, *p<0.05 using two-way analysis of variance); ( E ) <t>IncuCyte</t> killing assay of 2.5:1 ratio of CD8 + CAR T cells co-cultured with adult U251CL glioma cells or pediatric SU-DIPG36GL tumor cells over 24 hours. Transduction efficiencies for CD8+ GFP+ (empty vector) or CD8+ G4S+ CAR T cells for each group are as follows: EV 41%, HER2 43%, EphA3 25%. CAR, chimeric antigen receptor; EphA3, Ephrin type-A receptor 3; HER2, Human epidermal receptor protein 2; IFNγ, interferon gamma; scFv, single-chain variable fragment; TNF, Tumour necrosis factor.
V2021b, supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/v2021b/product/MathWorks Inc
Average 90 stars, based on 1 article reviews
v2021b - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
cavalieri estimator  (MBF Bioscience)
90
MBF Bioscience cavalieri estimator
EphA3 CAR T cells are functional against adult and pediatric glioma. ( A ) Schematic of second generation CAR constructs; ( B ) flow cytometry of cell surface expression of EphA3 (red) and HER2 (blue) CAR, as detected using anti-G4S protein tag antibody, and the percentage of CAR+ of T-cell population shown for three independent human donors; activated CD4 + EphA3-CAR T cells after 16 hour co-culture with U251CL tumor cells, or CD3/CD28 beads as positive control showing ( C ) %CD137 expression as detected using flow cytometry and ( D ) IFNγ and TNF secretion (pg/mL) into the culture. Transduction efficiencies of CD4+ GFP+ (empty vector) or CD4+ G4S+ CAR T cells shown in ( C ) and ( D ) for each group are as follows: EV 62%, HER2 94%, EphA3 79%. Shown is mean of triplicates (n=3± STDEV, *p<0.05 using two-way analysis of variance); ( E ) <t>IncuCyte</t> killing assay of 2.5:1 ratio of CD8 + CAR T cells co-cultured with adult U251CL glioma cells or pediatric SU-DIPG36GL tumor cells over 24 hours. Transduction efficiencies for CD8+ GFP+ (empty vector) or CD8+ G4S+ CAR T cells for each group are as follows: EV 41%, HER2 43%, EphA3 25%. CAR, chimeric antigen receptor; EphA3, Ephrin type-A receptor 3; HER2, Human epidermal receptor protein 2; IFNγ, interferon gamma; scFv, single-chain variable fragment; TNF, Tumour necrosis factor.
Cavalieri Estimator, supplied by MBF Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cavalieri estimator/product/MBF Bioscience
Average 90 stars, based on 1 article reviews
cavalieri estimator - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
matlab v2021b  (MathWorks Inc)
90
MathWorks Inc matlab v2021b
EphA3 CAR T cells are functional against adult and pediatric glioma. ( A ) Schematic of second generation CAR constructs; ( B ) flow cytometry of cell surface expression of EphA3 (red) and HER2 (blue) CAR, as detected using anti-G4S protein tag antibody, and the percentage of CAR+ of T-cell population shown for three independent human donors; activated CD4 + EphA3-CAR T cells after 16 hour co-culture with U251CL tumor cells, or CD3/CD28 beads as positive control showing ( C ) %CD137 expression as detected using flow cytometry and ( D ) IFNγ and TNF secretion (pg/mL) into the culture. Transduction efficiencies of CD4+ GFP+ (empty vector) or CD4+ G4S+ CAR T cells shown in ( C ) and ( D ) for each group are as follows: EV 62%, HER2 94%, EphA3 79%. Shown is mean of triplicates (n=3± STDEV, *p<0.05 using two-way analysis of variance); ( E ) <t>IncuCyte</t> killing assay of 2.5:1 ratio of CD8 + CAR T cells co-cultured with adult U251CL glioma cells or pediatric SU-DIPG36GL tumor cells over 24 hours. Transduction efficiencies for CD8+ GFP+ (empty vector) or CD8+ G4S+ CAR T cells for each group are as follows: EV 41%, HER2 43%, EphA3 25%. CAR, chimeric antigen receptor; EphA3, Ephrin type-A receptor 3; HER2, Human epidermal receptor protein 2; IFNγ, interferon gamma; scFv, single-chain variable fragment; TNF, Tumour necrosis factor.
Matlab V2021b, supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/matlab v2021b/product/MathWorks Inc
Average 90 stars, based on 1 article reviews
matlab v2021b - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
abaqus v2021  (Abaqus Inc)
90
Abaqus Inc abaqus v2021
EphA3 CAR T cells are functional against adult and pediatric glioma. ( A ) Schematic of second generation CAR constructs; ( B ) flow cytometry of cell surface expression of EphA3 (red) and HER2 (blue) CAR, as detected using anti-G4S protein tag antibody, and the percentage of CAR+ of T-cell population shown for three independent human donors; activated CD4 + EphA3-CAR T cells after 16 hour co-culture with U251CL tumor cells, or CD3/CD28 beads as positive control showing ( C ) %CD137 expression as detected using flow cytometry and ( D ) IFNγ and TNF secretion (pg/mL) into the culture. Transduction efficiencies of CD4+ GFP+ (empty vector) or CD4+ G4S+ CAR T cells shown in ( C ) and ( D ) for each group are as follows: EV 62%, HER2 94%, EphA3 79%. Shown is mean of triplicates (n=3± STDEV, *p<0.05 using two-way analysis of variance); ( E ) <t>IncuCyte</t> killing assay of 2.5:1 ratio of CD8 + CAR T cells co-cultured with adult U251CL glioma cells or pediatric SU-DIPG36GL tumor cells over 24 hours. Transduction efficiencies for CD8+ GFP+ (empty vector) or CD8+ G4S+ CAR T cells for each group are as follows: EV 41%, HER2 43%, EphA3 25%. CAR, chimeric antigen receptor; EphA3, Ephrin type-A receptor 3; HER2, Human epidermal receptor protein 2; IFNγ, interferon gamma; scFv, single-chain variable fragment; TNF, Tumour necrosis factor.
Abaqus V2021, supplied by Abaqus Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/abaqus v2021/product/Abaqus Inc
Average 90 stars, based on 1 article reviews
abaqus v2021 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
matlab v.2021a  (MathWorks Inc)
90
MathWorks Inc matlab v.2021a
EphA3 CAR T cells are functional against adult and pediatric glioma. ( A ) Schematic of second generation CAR constructs; ( B ) flow cytometry of cell surface expression of EphA3 (red) and HER2 (blue) CAR, as detected using anti-G4S protein tag antibody, and the percentage of CAR+ of T-cell population shown for three independent human donors; activated CD4 + EphA3-CAR T cells after 16 hour co-culture with U251CL tumor cells, or CD3/CD28 beads as positive control showing ( C ) %CD137 expression as detected using flow cytometry and ( D ) IFNγ and TNF secretion (pg/mL) into the culture. Transduction efficiencies of CD4+ GFP+ (empty vector) or CD4+ G4S+ CAR T cells shown in ( C ) and ( D ) for each group are as follows: EV 62%, HER2 94%, EphA3 79%. Shown is mean of triplicates (n=3± STDEV, *p<0.05 using two-way analysis of variance); ( E ) <t>IncuCyte</t> killing assay of 2.5:1 ratio of CD8 + CAR T cells co-cultured with adult U251CL glioma cells or pediatric SU-DIPG36GL tumor cells over 24 hours. Transduction efficiencies for CD8+ GFP+ (empty vector) or CD8+ G4S+ CAR T cells for each group are as follows: EV 41%, HER2 43%, EphA3 25%. CAR, chimeric antigen receptor; EphA3, Ephrin type-A receptor 3; HER2, Human epidermal receptor protein 2; IFNγ, interferon gamma; scFv, single-chain variable fragment; TNF, Tumour necrosis factor.
Matlab V.2021a, supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/matlab v.2021a/product/MathWorks Inc
Average 90 stars, based on 1 article reviews
matlab v.2021a - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
discovery studio visualizer v2021  (Accelrys)
90
Accelrys discovery studio visualizer v2021
EphA3 CAR T cells are functional against adult and pediatric glioma. ( A ) Schematic of second generation CAR constructs; ( B ) flow cytometry of cell surface expression of EphA3 (red) and HER2 (blue) CAR, as detected using anti-G4S protein tag antibody, and the percentage of CAR+ of T-cell population shown for three independent human donors; activated CD4 + EphA3-CAR T cells after 16 hour co-culture with U251CL tumor cells, or CD3/CD28 beads as positive control showing ( C ) %CD137 expression as detected using flow cytometry and ( D ) IFNγ and TNF secretion (pg/mL) into the culture. Transduction efficiencies of CD4+ GFP+ (empty vector) or CD4+ G4S+ CAR T cells shown in ( C ) and ( D ) for each group are as follows: EV 62%, HER2 94%, EphA3 79%. Shown is mean of triplicates (n=3± STDEV, *p<0.05 using two-way analysis of variance); ( E ) <t>IncuCyte</t> killing assay of 2.5:1 ratio of CD8 + CAR T cells co-cultured with adult U251CL glioma cells or pediatric SU-DIPG36GL tumor cells over 24 hours. Transduction efficiencies for CD8+ GFP+ (empty vector) or CD8+ G4S+ CAR T cells for each group are as follows: EV 41%, HER2 43%, EphA3 25%. CAR, chimeric antigen receptor; EphA3, Ephrin type-A receptor 3; HER2, Human epidermal receptor protein 2; IFNγ, interferon gamma; scFv, single-chain variable fragment; TNF, Tumour necrosis factor.
Discovery Studio Visualizer V2021, supplied by Accelrys, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/discovery studio visualizer v2021/product/Accelrys
Average 90 stars, based on 1 article reviews
discovery studio visualizer v2021 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
amira v2021.3  (Thermo Fisher)
90
Thermo Fisher amira v2021.3
EphA3 CAR T cells are functional against adult and pediatric glioma. ( A ) Schematic of second generation CAR constructs; ( B ) flow cytometry of cell surface expression of EphA3 (red) and HER2 (blue) CAR, as detected using anti-G4S protein tag antibody, and the percentage of CAR+ of T-cell population shown for three independent human donors; activated CD4 + EphA3-CAR T cells after 16 hour co-culture with U251CL tumor cells, or CD3/CD28 beads as positive control showing ( C ) %CD137 expression as detected using flow cytometry and ( D ) IFNγ and TNF secretion (pg/mL) into the culture. Transduction efficiencies of CD4+ GFP+ (empty vector) or CD4+ G4S+ CAR T cells shown in ( C ) and ( D ) for each group are as follows: EV 62%, HER2 94%, EphA3 79%. Shown is mean of triplicates (n=3± STDEV, *p<0.05 using two-way analysis of variance); ( E ) <t>IncuCyte</t> killing assay of 2.5:1 ratio of CD8 + CAR T cells co-cultured with adult U251CL glioma cells or pediatric SU-DIPG36GL tumor cells over 24 hours. Transduction efficiencies for CD8+ GFP+ (empty vector) or CD8+ G4S+ CAR T cells for each group are as follows: EV 41%, HER2 43%, EphA3 25%. CAR, chimeric antigen receptor; EphA3, Ephrin type-A receptor 3; HER2, Human epidermal receptor protein 2; IFNγ, interferon gamma; scFv, single-chain variable fragment; TNF, Tumour necrosis factor.
Amira V2021.3, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/amira v2021.3/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
amira v2021.3 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


EphA3 CAR T cells are functional against adult and pediatric glioma. ( A ) Schematic of second generation CAR constructs; ( B ) flow cytometry of cell surface expression of EphA3 (red) and HER2 (blue) CAR, as detected using anti-G4S protein tag antibody, and the percentage of CAR+ of T-cell population shown for three independent human donors; activated CD4 + EphA3-CAR T cells after 16 hour co-culture with U251CL tumor cells, or CD3/CD28 beads as positive control showing ( C ) %CD137 expression as detected using flow cytometry and ( D ) IFNγ and TNF secretion (pg/mL) into the culture. Transduction efficiencies of CD4+ GFP+ (empty vector) or CD4+ G4S+ CAR T cells shown in ( C ) and ( D ) for each group are as follows: EV 62%, HER2 94%, EphA3 79%. Shown is mean of triplicates (n=3± STDEV, *p<0.05 using two-way analysis of variance); ( E ) IncuCyte killing assay of 2.5:1 ratio of CD8 + CAR T cells co-cultured with adult U251CL glioma cells or pediatric SU-DIPG36GL tumor cells over 24 hours. Transduction efficiencies for CD8+ GFP+ (empty vector) or CD8+ G4S+ CAR T cells for each group are as follows: EV 41%, HER2 43%, EphA3 25%. CAR, chimeric antigen receptor; EphA3, Ephrin type-A receptor 3; HER2, Human epidermal receptor protein 2; IFNγ, interferon gamma; scFv, single-chain variable fragment; TNF, Tumour necrosis factor.

Journal: Journal for Immunotherapy of Cancer

Article Title: EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses

doi: 10.1136/jitc-2024-009486

Figure Lengend Snippet: EphA3 CAR T cells are functional against adult and pediatric glioma. ( A ) Schematic of second generation CAR constructs; ( B ) flow cytometry of cell surface expression of EphA3 (red) and HER2 (blue) CAR, as detected using anti-G4S protein tag antibody, and the percentage of CAR+ of T-cell population shown for three independent human donors; activated CD4 + EphA3-CAR T cells after 16 hour co-culture with U251CL tumor cells, or CD3/CD28 beads as positive control showing ( C ) %CD137 expression as detected using flow cytometry and ( D ) IFNγ and TNF secretion (pg/mL) into the culture. Transduction efficiencies of CD4+ GFP+ (empty vector) or CD4+ G4S+ CAR T cells shown in ( C ) and ( D ) for each group are as follows: EV 62%, HER2 94%, EphA3 79%. Shown is mean of triplicates (n=3± STDEV, *p<0.05 using two-way analysis of variance); ( E ) IncuCyte killing assay of 2.5:1 ratio of CD8 + CAR T cells co-cultured with adult U251CL glioma cells or pediatric SU-DIPG36GL tumor cells over 24 hours. Transduction efficiencies for CD8+ GFP+ (empty vector) or CD8+ G4S+ CAR T cells for each group are as follows: EV 41%, HER2 43%, EphA3 25%. CAR, chimeric antigen receptor; EphA3, Ephrin type-A receptor 3; HER2, Human epidermal receptor protein 2; IFNγ, interferon gamma; scFv, single-chain variable fragment; TNF, Tumour necrosis factor.

Article Snippet: Results were analyzed using IncuCyte software (Sartorius, V.2021A).

Techniques: Functional Assay, Construct, Flow Cytometry, Expressing, Co-Culture Assay, Positive Control, Transduction, Plasmid Preparation, Cell Culture